Cancer treatments

Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa® (Tucatinib) and Chemotherapy

Retrieved on: 
Wednesday, July 28, 2021

Recent clinical trials have demonstrated the benefit of combining tucatinib with trastuzumab and chemotherapy in patients with metastatic HER2-positive breast cancer, said Neil Josephson, M.D., Interim Chief Medical Officer at Zymeworks.

Key Points: 
  • Recent clinical trials have demonstrated the benefit of combining tucatinib with trastuzumab and chemotherapy in patients with metastatic HER2-positive breast cancer, said Neil Josephson, M.D., Interim Chief Medical Officer at Zymeworks.
  • In addition, zanidatamab potently activates the immune system to elicit antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity.
  • Tucatinib is a tyrosine kinase inhibitor of HER2 and helps prevent the cancer cells from growing.
  • Zanidatamab is a bispecific antibody, based on Zymeworks Azymetric platform, that can simultaneously bind two non-overlapping epitopes of HER2, known as biparatopic binding.

Oncocyte to Report Second Quarter 2021 Financial Results on Tuesday, August 10

Retrieved on: 
Tuesday, July 27, 2021

The Company will host a conference call on Tuesday, August 10, 2021, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments.

Key Points: 
  • The Company will host a conference call on Tuesday, August 10, 2021, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments.
  • To access the live webcast, go to the investor relations section on the Companys website, or by clicking here: http://public.viavid.com/index.php?id=145975 .
  • The Companys tests are designed to help provide clarity and confidence to physicians and their patients at every stage of care.
  • DetermaRx identifies early-stage lung cancer patients who are at high risk for cancer recurrence and predicts benefit from adjuvant chemotherapy.

Infinity Pharmaceuticals Presents Updated Data from Phase 2 MARIO-275 Trial in Urothelial Cancer (UC) and Phase 2 MARIO-3 Trial in Triple Negative Breast Cancer (TNBC)

Retrieved on: 
Tuesday, July 27, 2021

These data provide preliminary, but compelling evidence of eganelisibs potential to improve outcomes for patients with these two types of cancer.

Key Points: 
  • These data provide preliminary, but compelling evidence of eganelisibs potential to improve outcomes for patients with these two types of cancer.
  • These results are consistent with the results from MARIO-275, which show the similar translation of disease control into a meaningful survival benefit for patients.
  • For patients with TNBC, the potential to extend progression free survival, regardless of PD-L1 status, would be a transformational breakthrough.
  • MARIO-275 is a global, randomized, controlled combination study of eganelisib combined with Opdivo in I/O nave urothelial cancer.

Fidia announces the FDA Orphan Drug designation for ONCOFID®-P for the treatment of malignant mesothelioma, the cancer caused by exposure to asbestos

Retrieved on: 
Monday, July 26, 2021

The loco-regional administration makes ONCOFID-P an ideal anticancer drug in combination with existing treatments for patients with malignant mesothelioma.

Key Points: 
  • The loco-regional administration makes ONCOFID-P an ideal anticancer drug in combination with existing treatments for patients with malignant mesothelioma.
  • ONCOFID-P is an anticancer drug in advanced clinical development for the loco-regional treatment of non-muscle invasive bladder cancer, on which it has already demonstrated potent efficacy and excellent tolerability.
  • The onset of mesothelioma is closely related to exposure to asbestos, used as an insulator in many industries, from constructions to naval-aircraft and heavy industries.
  • ONCOFID-P is an innovative anti-cancer drug, a conjugate of paclitaxel (taxol) with hyaluronic acid (HA), resulting from the research of Fidia Farmaceutici.

Lee’s Pharmaceutical Announces First Patient Dosed With its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, as a First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer

Retrieved on: 
Friday, July 23, 2021

Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by Lees Pharm.

Key Points: 
  • Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by Lees Pharm.
  • Socazolimab is a fully human anti-PD-L1 monoclonal antibody identified by Sorrento using its proprietary G-MAB library platform.
  • COF received exclusive rights to develop and commercialize the antibody for Greater China, which includes Mainland China, Hong Kong, Macau, and Taiwan.
  • Forward-looking statements include statements regarding the potential efficacy and safety profile of a Socazolimab product candidate in patients with extensive-stage small-cell lung cancer.

Eisai: FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma

Retrieved on: 
Friday, July 23, 2021

Based on the type and/or severity of the adverse reaction, LENVIMA may be interrupted, reduced and/or discontinued.

Key Points: 
  • Based on the type and/or severity of the adverse reaction, LENVIMA may be interrupted, reduced and/or discontinued.
  • Based on its mechanism of action and data from animal reproduction studies, LENVIMA can cause fetal harm when administered to a pregnant woman.
  • Based on the severity of the adverse reaction, KEYTRUDA should be withheld or permanently discontinued and corticosteroids administered if appropriate.
  • "Based on Phase 3 data, today's approval acts as the confirmatory trial to our previous accelerated approval of KEYTRUDA plus LENVIMA in patients with certain types of advanced endometrial cancer and reinforces the impact of our joint research with Eisai in exploring the potential of this combination to treat more patients with challenging types of cancer."

Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (ADG116 and ADG126) in Combination Therapy with KEYTRUDA® (pembrolizumab)

Retrieved on: 
Thursday, July 22, 2021

This collaboration with Merck and the advancement of our global clinical studies represent an important milestone in our comprehensive CTLA-4 clinical development program, said Peter Luo, Ph.D., Co-founder, Chief Executive Officer and Chairman of Adagene.

Key Points: 
  • This collaboration with Merck and the advancement of our global clinical studies represent an important milestone in our comprehensive CTLA-4 clinical development program, said Peter Luo, Ph.D., Co-founder, Chief Executive Officer and Chairman of Adagene.
  • We are fortunate to have the opportunity to explore this combination with Merck and tackle two of the most potent immunotherapy targets.
  • KEYTRUDA is a registered trademark ofMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,Kenilworth, NJ, USA.
  • In the ADG116-1003 trial, ADG116 has been well tolerated in 17 patients, with no dose-limiting toxicities or unexpected safety signals.

Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board

Retrieved on: 
Wednesday, July 21, 2021

REDWOOD CITY, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the appointment of Ildiko Csiki, M.D., Ph.D., a leader in the field of immuno-oncology research and drug development, as Chair of its Scientific Advisory Board (SAB).

Key Points: 
  • REDWOOD CITY, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the appointment of Ildiko Csiki, M.D., Ph.D., a leader in the field of immuno-oncology research and drug development, as Chair of its Scientific Advisory Board (SAB).
  • With Dr. Csiki as Chair, Coherus SAB will work closely with Coherus leadership to build a world-class immuno-oncology franchise that offers life-changing medicines to patients.
  • We are honored to have Dr. Csiki as Chair of our Scientific Advisory Board.
  • As a highly regarded and successful physician-scientist, she has made significant contributions to the development of several cancer immunotherapies, including pembrolizumab, said Denny Lanfear, CEO of Coherus.

NOXXON Pharma Enters Second Clinical Collaboration With MSD to Evaluate NOX-A12 in Combination With KEYTRUDA® (Pembrolizumab) in Upcoming Phase 2 Pancreatic Cancer Study

Retrieved on: 
Wednesday, July 21, 2021

This Phase 2 study will evaluate the safety and efficacy of NOX-A12, NOXXONs anti-CXCL12 agent, in combination with KEYTRUDA and two different chemotherapy regimens in patients with microsatellite stable pancreatic cancer.

Key Points: 
  • This Phase 2 study will evaluate the safety and efficacy of NOX-A12, NOXXONs anti-CXCL12 agent, in combination with KEYTRUDA and two different chemotherapy regimens in patients with microsatellite stable pancreatic cancer.
  • The vast majority of pancreatic cancer patients have microsatellite stable tumors which are resistant to checkpoint inhibitor monotherapy.
  • MSD will provide pembrolizumab and expert advice for the study protocol, while NOXXON will sponsor the trial that will be conducted in clinical centers in the US and Europe.
  • NOX-A12 is currently developed in second-line pancreatic cancer in combination with Keytruda and in glioblastoma in combination with radiotherapy.

Lumeda Announces Appointment of Jason Pesterfield to Board of Directors

Retrieved on: 
Tuesday, July 20, 2021

ROCKY HILL, Conn., July 20, 2021 /PRNewswire-PRWeb/ -- Lumeda Inc. , a medical technology company advancing Photodynamic Therapy (PDT) as an intraoperative adjuvant treatment for patients during lung cancer surgery, today announced the appointment of Jason Pesterfield to its board of directors.

Key Points: 
  • ROCKY HILL, Conn., July 20, 2021 /PRNewswire-PRWeb/ -- Lumeda Inc. , a medical technology company advancing Photodynamic Therapy (PDT) as an intraoperative adjuvant treatment for patients during lung cancer surgery, today announced the appointment of Jason Pesterfield to its board of directors.
  • "We are excited to have Jason join our board of directors to bring his deep experience in lung cancer surgery and global connections to thoracic surgeons and interventional pulmonologist," said Lumeda CEO, Sandy Zinke.
  • "Jason has significant expertise in developing innovative commercialization strategies to launch new medical technologies in the lung cancer space.
  • "I am excited to be joining the talented Lumeda team to help them introduce this important adjuvant therapy for treating lung cancer," said Pesterfield.